Literature DB >> 31101626

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.

Paolo Strati1, Loretta J Nastoupil1, Luis E Fayad1, Felipe Samaniego1, Sherry Adkins1, Sattva S Neelapu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31101626      PMCID： PMC7265784          DOI： 10.1182/blood.2019000888

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies.

Authors:  Luigino Dal Maso; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

3.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

Review 4.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

5.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

6.  Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.

Authors:  He Huang; Xueying Li; Jun Zhu; Sheng Ye; Hongyu Zhang; Wei Wang; Xiangyuan Wu; Jiewen Peng; Bing Xu; Yingcheng Lin; Yabing Cao; Haoran Li; Suxia Lin; Qing Liu; Tongyu Lin
Journal:  JAMA       Date:  2014-12-17       Impact factor: 56.272

Review 7.  Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis.

Authors:  A Nath; R Agarwal; P Malhotra; S Varma
Journal:  Intern Med J       Date:  2010-09       Impact factor: 2.048

8.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

9.  Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.

Authors:  Ji Won Park; Kyeong Min Kwak; Sung Eun Kim; Myoung Kuk Jang; Ki Tae Suk; Dong Joon Kim; Sang Hoon Park; Myung Seok Lee; Hyoung Su Kim; Choong Kee Park
Journal:  BMC Gastroenterol       Date:  2017-03-09       Impact factor: 3.067

10.  Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma.

Authors:  Jacqueline Estevez; Vincent L Chen; Ondrej Podlaha; Biao Li; An Le; Philip Vutien; Ellen T Chang; Yael Rosenberg-Hasson; Zhaoshi Jiang; Stefan Pflanz; Dongliang Ge; Anuj Gaggar; Mindie H Nguyen
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379
  10 in total
  14 in total

Review 1.  How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.

Authors:  Joshua A Hill; Susan K Seo
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 2.  Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Authors:  Kevin Tang; Loretta J Nastoupil
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

Review 3.  Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.

Authors:  Kitsada Wudhikarn; Miguel-Angel Perales
Journal:  Bone Marrow Transplant       Date:  2022-07-15       Impact factor: 5.174

Review 4.  Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.

Authors:  Mark B Leick; Marcela V Maus; Matthew J Frigault
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

5.  [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-06-14

6.  CAR-based cell therapy: evaluation with bibliometrics and patent analysis.

Authors:  Yajun Yuan; Qihan Fu; Yaqun Zhang; Danhai Xu; Yeqing Wu; Qiufei Qiu; Wuyuan Zhou
Journal:  Hum Vaccin Immunother       Date:  2021-06-29       Impact factor: 4.526

7.  Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Authors:  Ibrahim Yakoub-Agha; Christian Chabannon; Peter Bader; Grzegorz W Basak; Halvard Bonig; Fabio Ciceri; Selim Corbacioglu; Rafael F Duarte; Hermann Einsele; Michael Hudecek; Marie José Kersten; Ulrike Köhl; Jürgen Kuball; Stephan Mielke; Mohamad Mohty; John Murray; Arnon Nagler; Stephen Robinson; Riccardo Saccardi; Fermin Sanchez-Guijo; John A Snowden; Micha Srour; Jan Styczynski; Alvaro Urbano-Ispizua; Patrick J Hayden; Nicolaus Kröger
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

8.  Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.

Authors:  Jia Wei; Xiaojian Zhu; Xia Mao; Liang Huang; Fankai Meng; Jianfeng Zhou
Journal:  J Immunother Cancer       Date:  2019-11-21       Impact factor: 13.751

9.  Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus.

Authors:  Yongping Song; Quanli Gao; Lu Han; Jian Zhou; Keshu Zhou; Xinghu Zhu; Lingdi Zhao; Baijun Fang; Qingsong Yin; Xudong Wei; Hu Zhou; Linlin Li; Bengling Xu; Jishuai Zhang
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

Review 10.  Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper.

Authors:  Ibai Los-Arcos; Gloria Iacoboni; Manuela Aguilar-Guisado; Laia Alsina-Manrique; Cristina Díaz de Heredia; Claudia Fortuny-Guasch; Irene García-Cadenas; Carolina García-Vidal; Marta González-Vicent; Rafael Hernani; Mi Kwon; Marina Machado; Xavier Martínez-Gómez; Valentín Ortiz Maldonado; Carolina Pinto Pla; José Luis Piñana; Virginia Pomar; Juan Luis Reguera-Ortega; Miguel Salavert; Pere Soler-Palacín; Lourdes Vázquez-López; Pere Barba; Isabel Ruiz-Camps
Journal:  Infection       Date:  2020-09-26       Impact factor: 7.455
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.